GlobeNewswire BiotechOriginal article
Targeting The Mutant: NTHI’s NEO100 Data Could Open a New Front in the Fight Against Brain Cancer
Phase 2positiveNEO100Positive
AI Analysis
Summary
NeOnc's Phase 2a study of intranasal NEO100 met its primary endpoint in recurrent IDH1-mutant high-grade glioma, potentially opening new therapeutic avenues in brain cancer treatment.
Clinical Trial Data
Phase
2a
Primary Endpoint
Met
Outcome Details
Phase 2a study met primary endpoint
Importance:7/10
Sentiment:
0.80
Phase 2CNSoncologygliomaIDH1-mutantintranasal
Related Companies
Read the original article
Published by GlobeNewswire Biotech on August 12, 2026 1:38 PM